What is HBIO's health score?

HARVARD BIOSCIENCE INC (HBIO) has a TradeApes health score of 47 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is HBIO's estimated fair value?

Based on our 5-year discounted cash flow model, HARVARD BIOSCIENCE INC's estimated fair value is $35.23 per share, representing a 483.3% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is HBIO undervalued or overvalued?

Our model currently rates HBIO as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

4 free score cards remaining

HARVARD BIOSCIENCE INC (HBIO)

Healthcare Undervalued low mixed

$6.04

Updated: 2026-07-14

TradeApes Score

Financial Strength

20 Stressed

Operating Trend

48 Mixed

Relative Value

65 Healthy

Capital Allocation

55 Mixed

Risk Management

50 Mixed

Est. Fair Value $35.23

DCF Upside +483.3%

Sector Rank #7018 of 12113

Key Findings

+ High FCF yield — above 7%, strong cash return relative to price paid

Unlock Full Report →

− Very high leverage — net debt/EBITDA above 5×

Unlock Full Report →

Industry Related Stocks

AGILENT TECHNOLOGIES, INC. (A) Alamar Biosciences, Inc. (ALMR) ASTROTECH Corp (ASTC) Avantor, Inc. (AVTR) BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) BIO-RAD LABORATORIES, INC. (BIO)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.